Insider Transactions in Q1 2022 at Biogen Inc. (BIIB)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2022
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
659
-1.45%
|
$137,731
$209.79 P/Share
|
|
Feb 18
2022
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,485
+3.15%
|
-
|
|
Feb 18
2022
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-5.21%
|
$128,744
$209.79 P/Share
|
|
Feb 18
2022
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,387
+10.49%
|
-
|
|
Feb 18
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
879
-10.66%
|
$183,711
$209.79 P/Share
|
|
Feb 18
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
1,981
+19.38%
|
-
|
|
Feb 18
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
175
-9.07%
|
$36,575
$209.79 P/Share
|
|
Feb 18
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
594
+23.54%
|
-
|
|
Feb 18
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-6.31%
|
$24,453
$209.79 P/Share
|
|
Feb 18
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
396
+17.6%
|
-
|
|
Feb 18
2022
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
977
-18.08%
|
$204,193
$209.79 P/Share
|
|
Feb 18
2022
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,981
+26.82%
|
-
|
|
Feb 18
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
110
-6.23%
|
$22,990
$209.79 P/Share
|
|
Feb 18
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
371
+17.35%
|
-
|
|
Feb 18
2022
|
Michel Vounatsos Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,746
-3.92%
|
$573,914
$209.79 P/Share
|
|
Feb 18
2022
|
Michel Vounatsos Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,191
+8.12%
|
-
|
|
Feb 12
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-6.18%
|
$19,688
$214.59 P/Share
|
|
Feb 12
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
263
+15.02%
|
-
|
|
Feb 12
2022
|
Michel Vounatsos Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,566
-4.15%
|
$1,833,124
$214.59 P/Share
|
|
Feb 12
2022
|
Michel Vounatsos Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,716
+5.92%
|
-
|
|
Feb 12
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
171
-3.71%
|
$36,594
$214.59 P/Share
|
|
Feb 12
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
275
+8.16%
|
-
|
|
Feb 12
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-8.37%
|
$26,108
$214.59 P/Share
|
|
Feb 12
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
351
+19.41%
|
-
|
|
Feb 12
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
2,342
-10.34%
|
$501,188
$214.59 P/Share
|
|
Feb 12
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
2,597
+14.51%
|
-
|
|
Feb 12
2022
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,252
-3.76%
|
$267,928
$214.59 P/Share
|
|
Feb 12
2022
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,672
+6.99%
|
-
|
|
Feb 12
2022
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,056
-1.51%
|
$439,984
$214.59 P/Share
|
|
Feb 12
2022
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,280
+2.45%
|
-
|
|
Jan 19
2022
|
Michel Vounatsos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,594
+14.27%
|
-
|
|
Jan 19
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
244
+15.27%
|
-
|
|
Jan 19
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Grant, award, or other acquisition
|
Direct |
3,088
+33.95%
|
-
|
|
Jan 19
2022
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
1,941
+16.22%
|
-
|
|
Jan 19
2022
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Grant, award, or other acquisition
|
Direct |
658
+11.5%
|
-
|
|
Jan 19
2022
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,825
+6.05%
|
-
|